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Abstract
Background: Low frequency sensorineural hearing loss (LFSNHL) is an uncommon clinical finding.
Mutations within three different identified genes (DIAPH1, MYO7A, and WFS1) are known to cause
LFSNHL. The majority of hereditary LFSNHL is associated with heterozygous mutations in the
WFS1 gene (wolframin protein). The goal of this study was to use genetic analysis to determine if
a small American family's hereditary LFSNHL is linked to a mutation in the WFS1 gene and to use
VEMP and EcochG testing to further characterize the family's audiovestibular phenotype.
Methods: The clinical phenotype of the American family was characterized by audiologic testing,
vestibular evoked myogenic potentials (VEMP), and electrocochleography (EcochG) evaluation.
Genetic characterization was performed by microsatellite analysis and direct sequencing of WFS1
for mutation detection.
Results: Sequence analysis of the WFS1 gene revealed a novel heterozygous mutation at
c.2054G>C predicting a p.R685P amino acid substitution in wolframin. The c.2054G>C mutation
segregates faithfully with hearing loss in the family and is absent in 230 control chromosomes. The
p.R685 residue is located within the hydrophilic C-terminus of wolframin and is conserved across
species. The VEMP and EcochG findings were normal in individuals segregating the WFS1
c.2054G>C mutation.
Conclusion: We discovered a novel heterozygous missense mutation in exon 8 of WFS1
predicting a p.R685P amino acid substitution that is likely to underlie the LFSNHL phenotype in the
American family. For the first time, we describe VEMP and EcochG findings for individuals
segregating a heterozygous WFS1 mutation.
Background
Hearing loss is a common disorder affecting the commu-
nication abilities of more than 28 million Americans. A
variety of etiologies for hearing loss have been identified
including aging, noise exposure, ototoxic medications,
and genetics. Over 90 different genetic loci have been
linked to hereditary auditory impairment [1]. The major-
ity of these loci are associated with high frequency hearing
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loci linked to low frequency hearing loss. It is not well
understood why autosomal dominant mutations at these
four loci cause low frequency hearing loss as opposed to
reduced sensitivity in the higher frequencies.
Non-syndromic autosomal dominant low frequency sen-
sorineural hearing loss (LFSNHL) has been mapped to the
DFNA1, DFNA11, DFNA54, and DFNA6/14/38 loci. These
four loci are described by the letters DFN, which stand for
deafness, and the letter A to indicate autosomal dominant
inheritance. The loci are labeled with a number indicating
the order in which they were discovered. DFNA1, the first
identified locus for LFSNHL, is associated with a mutation
in the DIAPH1 gene (homologue of Drosophila diapha-
nous) and has been reported in only a single family [2].
DFNA11 represents a second LFSNHL locus, where a het-
erozygous mutation in myosin VIIA (MYO7A) found in
only a single family leads to non-syndromic LFSNHL [3].
DFNA54 was mapped to LFSNHL in one family, but the
gene has not yet been identified [4]. The fourth and most
common locus for LFSNHL is DFNA6/14/38, which
results from heterozygous mutations in the Wolfram syn-
drome type 1 gene (WFS1) [5-7].
The hearing loss associated with autosomal dominant
mutations in WFS1 is primarily bilateral and symmetric.
The age of onset of hearing loss appears to occur before
age 10 and initially affects 250, 500 and 1000 Hz [8]. The
mild hearing loss in the low frequencies seen in young
children generally progresses to a moderate hearing loss
in the low and mid frequencies by the second decade of
life and then to a moderate to severe loss across the fre-
quency range after age 40 [7]. Homozygous mutations in
WFS1 have been linked to the recessively inherited Wolf-
ram syndrome, a syndrome whose features include diabe-
tes insipidus, diabetes mellitus, optic atrophy and
sensorineural hearing loss in the high frequencies [9].
WFS1 encodes for wolframin, an 890 amino acid protein
of unknown function, which has been localized to the
endoplasmic reticulum [10]. Wolframin is predicted to
have nine transmembrane spanning domains with a
hydrophilic N- and C-terminus [11]. Wolframin is
expressed in the mouse inner ear throughout postnatal
development (P1, 7, 14, 35) in a variety of cell types
including outer and inner hair cells, support cells, spiral
ganglion neurons and vestibular hair cells [12]. No wolf-
ramin expression gradient is observed between the apical
and basal ends of the cochlea.
Despite high levels of wolframin expression in the vestib-
ular hair cells [12], individuals with heterozygous WFS1
mutations and LFSNHL generally do not complain of ves-
tibular difficulty [7,8,13-17]. Ocular motor, caloric and
vestibular ocular reflex testing have not revealed any con-
sistent vestibular dysfunction in patients with Wolfram's
syndrome or individuals with heterozygous WFS1 muta-
tions and LFSNHL [15,17-21]. Previous vestibular testing
for individuals with heterozygous and homozygous WFS1
mutations has targeted the semicircular canals. To our
knowledge, no clinical testing of otolith function such as
the vestibular evoked myogenic potential (VEMP) has
been completed in individuals with WFS1 mutations. In
addition, the literature does not report electrocochleogra-
phy (EcochG) findings for individuals with WFS1 muta-
tions even though LFSNHL has also been associated with
endolymphatic hydrops [22].
The goal of this study was to use genetic analysis to deter-
mine if a small American family's hereditary LFSNHL is
linked to a mutation in the WFS1 gene and to use VEMP
and EcochG testing to further characterize the family's
audiovestibular phenotype.
Methods
Research subjects and controls
To facilitate microsatellite and sequence analysis, blood
samples were collected by venipuncture from four unaf-
fected and three affected family members and 115 pre-
dominantly Caucasian control subjects for high
molecular weight DNA isolation using standard tech-
niques. Control subjects were screened to ensure that they
had normal hearing for their age as previously described
[3]. Individuals gave written informed consent according
to a protocol approved by the Institutional Review Board
(IRB) of the University of Washington.
Auditory assessment
Audiologic evaluations were either conducted as part of
this study or obtained from previous test results that were
released to the study. Audiograms were obtained by a cer-
tified audiologist for seven affected members of the family
in either a sound treated booth or a quiet room during a
family reunion. Immittance testing was used to evaluate
middle-ear pressure, ear canal volume, and tympanic
membrane mobility. Each study participant completed a
hearing and balance questionnaire to assess his or her
medical and noise-exposure history.
VEMP and EcochG assessment
The VEMP and EcochG evaluations were conducted in the
Otolaryngology – HNS Clinic testing suites at the Univer-
sity of Washington. Vestibular Evoked Myogenic Potential
(VEMP) uses a high intensity auditory stimulus to elicit a
neck muscle response for assessment of saccular function.
Abnormal saccular function is indicated by the absence of
the VEMP response. Person 20 was presented monaurally
with 250 clicks at 5 Hz and 100 dB nHL. Potentials across
the ventral neck muscles were recorded bilaterally usingPage 2 of 6
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ography (EcochG) measures an auditory evoked response
generated by the cochlea and auditory nerve. The EcochG
response consists of the cochlear microphonic, the sum-
mating potential (SP), and the action potential (AP). An
increased SP/AP amplitude ratio is often used as a diag-
nostic indicator of endolymphatic hydrops and Meniere's
disease. Persons 20 and 26 were tested using the Nicolet
Spirit evoked potential system. Electrodes were placed on
the forehead and tiptrodes inserted into the ear canals.
Click stimuli were presented at a rate of 11.4 per second.
Response waveforms were obtained for an alternating
polarity stimulus over a 10 ms time window and for con-
densation and rarefaction stimuli over 5 ms. Responses
were recorded with filter settings of 20–3000 Hz and aver-
aged over 800–1000 sweeps.
Microsatellite marker, DNA sequence, and protein 
bioinformatics analysis
Microsatellite markers near the DFNA1, DFNA11,
DFNA4/16/38 and DFNA54 loci were analyzed in seven
family members. PCR products were multiplexed and sep-
arated by capillary electrophoresis on an ABI PRISM 310
Genetic Analyzer (PE Biosystems, Foster City, CA). Ampli-
fication products were sized according to CEPH (Centre
d'Etude du Polymorphisme Humain) control DNA
(1347-02) and assigned allele numbers consistent with
the CEPH designations [23]. The inheritance pattern of
the hearing loss was assumed to be autosomal dominant
and fully penetrant.
PCR primers for exons 1–8 and the immediate intron
flanking regions were designed with the Primer 3 web-
based program [24] and used to analyze the WFS1 gene in
one unaffected and two affected family members (primer
sequences available upon request). PCR incubation mix-
ture, thermocycling conditions, and purification proce-
dures for genomic amplification and sequencing were
performed as described previously [25,26]. Electrophero-
grams were analyzed using the CodonCode Aligner soft-
ware package (CodonCode Corporation, Dedham, MA).
The C-terminus region of wolframin (amino acids 657–
890) was analyzed using The PSIPRED Structure Predic-
tion Server [27-32] and FoldIndex [33].
Results
Low-frequency hearing loss
Affected family members demonstrated bilateral symmet-
ric moderate or moderately-severe sensorineural hearing
loss in the low frequencies, rising to normal or borderline
normal at 4000 Hz and above (Fig. 1A). A moderate low
frequency hearing loss found in a 4-year-old child sug-
gests childhood onset of hearing loss (Fig. 1A). Longitudi-
nal audiometric time points were available for females 20,
26, and 27 suggesting a slow rate of hearing loss progres-
sion in these three individuals (Fig. 1A). Speech audiom-
etry results for two family members indicated speech
discrimination ability within normal limits.
Genetic analysis supports novel mutation in WFS1 exon 8
Microsatellite markers near the DFNA1, DFNA11, and
DFNA54 loci did not cosegregate with hearing loss in the
American pedigree. However, allele 6 (234 bp product)
for marker D4S432 near the DFNA4/16/38 locus did
cosegregate with hearing loss in the family, leading us to
consider further the candidacy of the WFS1 gene by direct
sequence analysis. Sequencing of WFS1 exon 8 revealed a
c.2054G>C transversion (Fig. 1B) predicting a p.R685P
amino acid substitution (Fig. 1C). Sequence analysis indi-
cated the absence of this transversion in 230 control chro-
mosomes. This heterozygous c.2054G>C change is
consistent with the autosomal dominant inheritance
observed for hearing loss in the family (Fig. 1A). The
p.R685 residue is located within the hydrophilic C-termi-
nus of wolframin and conserved across human, rhesus
monkey, dog, cow, mouse, rat, opossum, chicken and frog
(Fig. 1C).
Protein bioinformatics predicts a folded Wolframin C-
terminus
Conserved structural protein motifs have not been identi-
fied in the C-terminus region of wolframin nor has a
solved protein structure for this region been published. In
this report, the C-terminus region of wolframin was ana-
lyzed using The PSIPRED Structure Prediction Server and
FoldIndex. These protein bioinformatics programs sug-
gest that the C-terminal region of wolframin adopts a
folded confirmation. It is likely that the p.R685 residue is
exposed on the surface of this folded domain where it
could facilitate protein-to-protein interactions.
Normal VEMP, and EcochG findings
No balance problems were self-reported by the family
members on the intake questionnaire. The VEMP was
present bilaterally in person 20. The EcochG test gener-
ated an SP/AP ratio within the normal range for both per-
sons 20 and 26.
Discussion
We identified a small Caucasian American family with
hereditary autosomal dominant LFSNHL likely caused by
a novel heterozygous c.2054G>C WFS1 mutation. The
absence of this heterozygous c.2054G>C DNA alteration
in 230 control chromosomes supports the hypothesis that
it represents a causative mutation, not a rare polymor-
phism. The c.2054G>C DNA alteration cosegregates faith-
fully with hearing loss in the family and predicts a non-
conservative p.R685P amino acid substitution in the wolf-
ramin protein. The arginine amino acid residue at posi-Page 3 of 6
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Audiologic and genetic characterization of the low frequency hearing loss pedigreeFigure 1
Audiologic and genetic characterization of the low frequency hearing loss pedigree. (A) Each individual in the ped-
igree is assigned a number. Underlined numbers indicate that auditory evaluations were performed for that person. Affected 
individuals are denoted by blackened symbols, males are denoted by squares, females are denoted by circles, and deceased per-
sons are indicated by a diagonal line through the symbol. Blood drop symbols indicate individuals who donated a blood sample 
to the study. Symmetrical hearing loss was detected in all affected family members; therefore, only the right ear pure-tone air 
conduction thresholds are plotted on the audiograms. Frequency in hertz (Hz) is plotted on the x-axis and the hearing level in 
decibels (dB HL) on the y-axis. Plotted on each audiogram (gray line) are the average pure-tone air conduction thresholds for 
a person with normal hearing matched in age [39] to the family member. (B) Electropherograms showing a heterozygous 
c.2054G>C mutated genomic nucleotide sequence from an affected individual compared to a homozygous c.2054G unaffected 
family member. Nucleotide numbering starts with the ORF. (C) Protein alignment shows conservation of the p.R685 residue 
during evolution. The p.685P substitution in the pedigree is shown in red.
BMC Medical Genetics 2008, 9:48 http://www.biomedcentral.com/1471-2350/9/48tion 685 is found not only in humans, but also in the
rhesus monkey, mouse, rat, dog, cow, opossum, chicken
and frog. Conservation of p.R685 over evolutionary time
suggests that altering this residue could have deleterious
consequences for the wolframin protein. The p.R685P
amino acid substitution may alter the ability of the C-ter-
minus domain to adopt a folded conformation or may
impede interaction with a protein binding partner. A
recent report using a yeast two-hybrid system with a
human brain cDNA library suggests that the C-terminal
domain (amino acids 652–890) of the human WFS1 gene
interacts with the Na+/K+ ATPase β1 subunit [34]. If a sim-
ilar association exists within the inner ear, perhaps the
p.R685P substitution alters this protein-to-protein inter-
action.
Twenty-six other heterozygous WFS1 mutations linked to
dominant low frequency sensorineural hearing loss have
been described previously [35]. These known mutations
include 25 point mutations and one small deletion, all
found in the large exon 8 with the exception of two point
mutations in exon 5. This wealth of mutational genetic
heterogeneity within WFS1 will contribute useful infor-
mation for uncovering the structure/function relationship
of the wolframin protein in the auditory and vestibular
system.
Previous vestibular testing focusing on semicircular canal
function in individuals with WFS1 mutations yielded nor-
mal findings [15,17-21]. However, saccular dysfunction
as assessed by the VEMP test has been shown to co-exist
with normal semicircular canal responses in patients with
connexin-26 mutations who do not complain of dizziness
or unsteadiness [36] and in some patients with Meniere's
disease who have normal caloric responses [37,38]. Given
that normal semicircular canal function as assessed by
clinical vestibular testing can not predict saccular func-
tion, the VEMP evaluation was extended to individuals
with heterozygous WFS1 mutations and LFSNHL in this
study for the first time. No saccular dysfunction was
detected in person 26 segregating the c.2054G>C WFS1
mutation as this individual generated a normal VEMP
response in both ears. This finding is interesting given that
wolframin is expressed in vestibular hair cells [12] of the
saccule (Guy van Camp, personal communication, 2007).
LFSNHL has also been associated with endolymphatic
hydrops. An 8-year-old boy with LFSNHL and a DIAPH1
mutation was evaluated with EcochG and found to have
an elevated SP/AP ratio, suggestive of endolymphatic
hydrops [22]. To determine if abnormal EcochG findings
were a trait of other dominant LFSNHL mutations, we
provided two individuals segregating the c.2054G>C
WFS1 mutation with an EcochG evaluation. The SP/AP
ratio was normal for both persons 20 and 26, which sug-
gests the absence of endolymphatic hydrops in these two
individuals. It would be interesting to follow-up with the
young man segregating the DIAPH1 mutation and other
individuals in his family affected by LFSNHL to determine
if an elevated EcochG SP/AP ratio is characteristic of the
DIAPH1 mutation.
Conclusion
We identified a small Caucasian American family present-
ing with hereditary autosomal dominant LFSNHL.
Genetic analysis of the family revealed a heterozygous
c.2054G>C WFS1 mutation that cosegregates with the
hearing loss found in the family. This mutation, absent in
230 control chromosomes, predicts a non-conservative
p.R685P substitution. For the first time, we describe
VEMP and EcochG findings for individuals segregating a
heterozygous WFS1 mutation, with both diagnostic tests
yielding normal findings in this family.
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